Guggenheim initiated coverage on Impel NeuroPharma with a new price target
$IMPL
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of Impel NeuroPharma with a rating of Buy and set a new price target of $32.00
Save time and jump to the most important pieces.